News
CASIF
0.150
+23.97%
0.029
Weekly Report: what happened at CASIF last week (0406-0410)?
Weekly Report · 1d ago
Weekly Report: what happened at CASIF last week (0330-0403)?
Weekly Report · 04/06 10:36
Weekly Report: what happened at CASIF last week (0323-0327)?
Weekly Report · 03/30 10:37
Weekly Report: what happened at CASIF last week (0316-0320)?
Weekly Report · 03/23 10:32
Weekly Report: what happened at CASIF last week (0309-0313)?
Weekly Report · 03/16 10:31
Small-Cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 03/13 13:55
Weekly Report: what happened at CASIF last week (0302-0306)?
Weekly Report · 03/09 10:32
CASI Pharmaceuticals CEO David Cory to Step Down; Executive Chairman Wei-Wu He Assumes Top Role
TipRanks · 03/03 14:39
Weekly Report: what happened at CASIF last week (0223-0227)?
Weekly Report · 03/02 10:31
*News On CASI Pharmaceuticals Inc. (CASI) Now Under CASIF
Dow Jones · 02/26 22:08
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 02/25 21:07
BUZZ-U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
Reuters · 02/25 18:48
Nasdaq Gains Over 1%; TJX Posts Upbeat Earnings
Benzinga · 02/25 17:46
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 02/25 17:05
BUZZ-U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
Reuters · 02/25 15:46
CASI Pharmaceuticals to Be Delisted From Nasdaq, Shares Expected to Move to OTC Market
TipRanks · 02/25 14:57
Dow Jumps 200 Points; Lowe's Issues Weak Earnings Outlook
Benzinga · 02/25 14:55
Casi Pharmaceuticals receives delisting decision from Nasdaq
TipRanks · 02/25 14:31
CASI Pharmaceuticals to be delisted from Nasdaq, shares to move to OTC Market
Seeking Alpha · 02/25 14:08
More
Webull provides a variety of real-time CASIF stock news. You can receive the latest news about Casi Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CASIF
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.